Literature DB >> 10728317

The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy.

P A van Zwieten1.   

Abstract

Left ventricular hypertrophy (LVH) has been recognized as an important cardiovascular risk factor. Hypertensive disease is the most frequent background of LVH and it is generally felt that anti-hypertensive treatment should not only lower blood pressure but also cause regression of LVH. In the present survey the patho-physiology of LVH, its measurements and animal models used to study LVH are briefly discussed. Subsequently, the effects of various drugs in animal models and in human hypertensives are reviewed. It has been shown repeatedly that various types of antihypertensive drugs show differential activities on the prevention or regression of LVH. It is not only the lowering of blood pressure which determines the anti-LVH activity, but also the interaction of drugs with neuro-endocrine mechanisms such as the renin-angiotensin-aldosterone system and the sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10728317     DOI: 10.1016/s0008-6363(99)00291-6

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  13 in total

Review 1.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Perindopril: an updated review of its use in hypertension.

Authors:  M Hurst; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Non-invasive assessment of cardiac function in a mouse model of renovascular hypertension.

Authors:  Federico Franchi; Bruce E Knudsen; Elise Oehler; Stephen C Textor; Lilach O Lerman; Joseph P Grande; Martin Rodriguez-Porcel
Journal:  Hypertens Res       Date:  2013-05-16       Impact factor: 3.872

4.  Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.

Authors:  Julian C Braz; Orlando F Bueno; Qiangrong Liang; Benjamin J Wilkins; Yan-Shan Dai; Stephanie Parsons; Joseph Braunwart; Betty J Glascock; Raisa Klevitsky; Thomas F Kimball; Timothy E Hewett; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 5.  Lacidipine: a review of its use in the management of hypertension.

Authors:  Paul L McCormack; Antona J Wagstaff
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Resveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein.

Authors:  Yuhua Fan; Li Liu; Kun Fang; Tao Huang; Lin Wan; Youbin Liu; Sen Zhang; Dongxia Yan; Guangnan Li; Yanhui Gao; Yanjie Lv; Yanjun Chen; Yingfeng Tu
Journal:  J Am Heart Assoc       Date:  2016-04-22       Impact factor: 5.501

7.  Protective effect of hydrogen-rich saline on pressure overload-induced cardiac hypertrophyin rats: possible role of JAK-STAT signaling.

Authors:  Zhixin Fan; Yufei Gao; Zhiwei Huang; Fenghua Xue; Shujing Wu; Jing Yang; Liqun Zhu; Lu Fu
Journal:  BMC Cardiovasc Disord       Date:  2018-02-13       Impact factor: 2.298

8.  Therapeutic efficacy of phentolamine in the management of severe hand, foot and mouth disease combined with pulmonary edema.

Authors:  Zhixin Yan; Yaokai Shang; Fengxian Li; Fei Xie; Huili Qian; Youqi Zhang; Bin Yue
Journal:  Exp Ther Med       Date:  2017-02-07       Impact factor: 2.447

9.  The effects of 17-methoxyl-7-hydroxy-benzene-furanchalcone on the pressure overload-induced progression of cardiac hypertrophy to cardiac failure.

Authors:  Jianchun Huang; XiaoJun Tang; Xingmei Liang; Qingwei Wen; Shijun Zhang; Feifei Xuan; Jie Jian; Xing Lin; Renbin Huang
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.752

10.  Gentisic acid attenuates pressure overload-induced cardiac hypertrophy and fibrosis in mice through inhibition of the ERK1/2 pathway.

Authors:  Simei Sun; Hae Jin Kee; Li Jin; Yuhee Ryu; Sin Young Choi; Gwi Ran Kim; Myung Ho Jeong
Journal:  J Cell Mol Med       Date:  2018-09-06       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.